Hyperacidified tumors having high .beta.-glucuronidase activity can be treated with glucuronides with aglycones toxic to the tumor cells with great safety toward the rest of the body by first administering an alkalinizing agent in an amount sufficient to maintain the pH level of non-tumor tissues at approximately 7.4 during the glucuronide treatment. This will cause inactivation of .beta.-glucuronidase activity in the rest of the body. When nitrile-containing aglycones are used sodium thiosulfate is also administered to avoid cyanide poisoning. A loading dose of glucuronide greater than 2 mMoles per kilogram body weight is first administered with additional administration of one third the initial dose each hour as long as .beta.-glucuronidase activity remains at the tumor site. Bacterial cells having .beta.-glucuronidase activity may also be diagnosed and treated in accordance with the present invention.

Schwimmer; Adolf

Schwartz; Irwin S.

Rubin; David

Century Science Corp.

Method for the treatment of tumors with .beta.-glucuronidase activity dependent pharmaceuticals

Hyperacidified tumors having high .beta.-glucuronidase activity can be treated with glucuronides with aglycones toxic to the tumor cells with great safety toward the rest of the body by first administering an alkalinizing agent in an amount sufficient to maintain the pH level of non-tumor tissues at approximately 7.4 during the glucuronide treatment. This will cause inactivation of .beta.-glucuronidase activity in the rest of the body. When nitrile-containing aglycones are used sodium thiosulfate is also administered to avoid cyanide poisoning. Novel glucuronides are disclosed the aglycones of which exert a higher toxic effect in an acid environment or are water-soluble only in an alkaline environment. Such compounds have particular utility with the above process. By substituting radioisotopes into the aglycone, diagnosis and in situ radiation therapy may be accomplished. Bacterial cells having .beta.-glucuronidase activity may also be diagnosed and treated in accordance with the present invention. A urine test is disclosed to determine the amount of free glucuronic acid in the urine which is an indication of the presence of a tumor in the body having high .beta.-glucuronidase activity. Novel methods of synthesizing the glucuronide used in the present invention are also disclosed.

Schwartz; Irwin Steven

A method of detecting a subject's cancer risk is provided. The method includes: gathering a sample of the subject's body water content via saliva; determining a ratio of cyanide within the subject's body water content and tissue saturation via saliva; providing a threshold cyanide ratio; comparing the ratio of cyanide within the subject's body water content and tissue saturation to the threshold cyanide ratio; and determining the patient's cancer risk based on the comparison of the ratio of cyanide within the subject's body water content to the threshold cyanide ratio.

Vigliotti; Anthony Sabato

Vigliotti; Salvatore Anthony

Method of detecting a risk of cancer

The invention relates to a new radiolabeled imaging agent, no-carrier-added [1-.sup.11 C]putrescine, and to the use of this very pure material as a radiotracer with positron emission tomography for imaging brain tumors. The invention further relates to the synthesis of no-carrier-added [1-.sup.11 C]putrescine based on the Michael addition of potassium .sup.11 C-labeled cyanide to acrylonitrile followed by reduction of the .sup.11 C-labeled dinitrile. The new method is rapid and efficient and provides radiotracer with a specific activity greater than 1.4 curies per millimol and in a purity greater than 95%.

cyanide/vēzis

Method for the treatment of tumors with .beta.-glucuronidase activity dependent pharmaceuticals

Method for the treatment of tumors with .beta.-glucuronidase activity dependent pharmaceuticals

Method of detecting a risk of cancer

No-carrier-added [1.sup.11 c]putrescine

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne